Prostate cancer incidence, mortality and survival trends in Estonia 1995–2014

Innos, Kaire; Baburin, Aleksei; Kotsar, Andres; Eiche, Ivar-Endrik; Lang, Kathy

doi:10.1016/s1569-9056(17)31364-7

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A rapid increase in prostate cancer incidence appears mostly to be associated with the widespread use of the PSA test since the middle of 1980s 3 5–7. PSA use in clinical practice in north-eastern European countries began in the mid-to-late 1990s which reportedly reached almost 70% of males in some populations 7 16 18 20. There were sporadic occurrences of prostate cancer screening in the study countries 19.…”

Section: Discussionmentioning

confidence: 95%

“…It is notable that similar incidence changes have been observed in Estonia, where the PSA uptake is relatively high in the male population, according to a health behaviour study reported in 2016 17. The role of PSA-testing in incidence trends is further supported by the fact that the incidence increase in Estonia was shown to be limited to localised cancers 16…”

Section: Discussionmentioning

confidence: 98%

“…Since the start of the programme in the period of 2006–2010, around 72%–78% of the total eligible male population received at least one PSA test. No official prostate cancer screening programme has been introduced in Estonia, although in clinical practice, primary care physicians routinely offer the test to middle-aged and elderly men, and patients themselves actively request the test 16. According to a population-based health behaviour survey in 2016, the proportion of men who reported to have never had a PSA test was nearly 50% in the age group 55–64 years, and nearly 60% in the age group 45–54 years 17.…”

Section: Discussionmentioning

confidence: 99%

“…In a study in Norway, over-reporting of prostate cancer deaths was estimated to be 33%, with significantly higher misattribution among older patients, who represent the large majority of prostate cancer deaths 28. Misattribution of the cause of death in Estonia was one explanation for increasing prostate cancer mortality 16…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine

et al. 2019

View full text Add to dashboard Cite

BackgroundProstate cancer incidence varies internationally largely attributable to differences in prostate-specific antigen (PSA) use. The aim of this study was to provide the most recent detailed international epidemiological comparison of prostate cancer incidence and mortality in six north-eastern European countries (Belarus, Estonia, Latvia, Lithuania, the Russian Federation and Ukraine).MethodsThe number of incident prostate cancer cases was obtained from the countries national cancer registries. Prostate cancer mortality and corresponding population data were extracted from the WHO Mortality Database. Age-specific and age-standardised incidence and mortality rates were calculated (European Standard). The joinpoint regression model was used to provide an average annual percentage change and to detect points in time where significant changes in trends occurred. The observation period was between 13 (Ukraine) and 48 (Estonia) years regarding incidence and around 30 years regarding mortality.ResultsThe comparison of prostate cancer incidence in six European countries showed almost sixfold differences in the age-adjusted rates in most recent years with highest incidence rates in Lithuania and Estonia. Through the observation period, overall a continuous rise was seen in incidence in all countries and a continuous rise in mortality, with a stabilisation in Estonia and a decrease in Lithuania in recent years. Data limitations included a descriptive design using ecological data.ConclusionsA widespread use of PSA testing seems to be responsible for the changes in the epidemiology of the disease in north-eastern European countries. Substantial variation in the incidence of prostate cancer in the Baltic states suggests the possibility that PSA performance and utilisation spread have had a major influence on observed incidence trends, with a lack of effect on prostate cancer mortality.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Prostate cancer is the most frequent male cancer in France and in Western countries. The general incidence has greatly increased owing to population ageing and the development of screening (Binder‐Foucard et al., 2014; Etxeberria et al., 2018; Innos et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of long‐term living conditions in patients treated for localised prostate cancer

Xiao¹,

Guizard

Daubisse‐Marliac

et al. 2020

Eur J Cancer Care

View full text Add to dashboard Cite

Purpose To evaluate the evolution of living conditions (LC) in long‐term survivors of localised prostate cancer 10 years after treatment compared with those of a same‐age control group from the general population. Methods Two hundred and eighty‐seven patients diagnosed with prostate cancer in 2001 were selected in 11 French cancer registries. They were matched with controls randomly selected for age and residency. Both patients and controls completed a self‐administered LC questionnaire concerning their familial, social and professional life, and general and specific quality of life (QoL) and anxiety and depression questionnaires. Results Compared with controls, patients reported more sexual modifications (p < .0001), but without any difference in marital status. Patients' circle of friends was more stable than that of the controls (91% vs. 63%; p < .0001) and patients reported fewer friendship modifications than controls (p < .0006). Their professional and physical activities were also preserved. They reported more anxiolytic intake (p = .002) but did not consult their general practitioner more often. Type of specialist consulted differed in the two groups. Conclusion Patients treated for localised prostate cancer had the same living conditions as men of the same age. Their social life was satisfying on the whole, albeit they reported more sexual difficulties than their counterparts.

show abstract

Incidence and Survival for Head and Neck Cancers in Estonia, 1996–2016: A Population-Based Study

Kase¹,

Baburin²,

Kuddu³

et al. 2021

CLEP

View full text Add to dashboard Cite

Background Changing patterns of alcohol and tobacco consumption and human papillomavirus (HPV) infection have affected the epidemiology of head and neck cancers. The aim of this study was to examine 20-year trends in the incidence and survival of head and neck cancers in Estonia by site, sex, morphology, and stage. Methods Data on all adult cases of invasive head and neck cancers diagnosed in Estonia in 1996–2016 were obtained from a population-based cancer registry. TNM stage was available for 2010–2016. Incidence trends were modeled with join-point regression, and five-year relative survival ratios (RSRs) were calculated. Results A total of 6,769 cases were included, 64% men. We observed declining incidence of lip and laryngeal cancer and substantial increases in the incidence of hypopharyngeal and oropharyngeal cancers. Over 60% of mouth and pharyngeal cancers were diagnosed at stage IV. Age-standardized 5-year RSR for mouth and pharyngeal cancer increased substantially over the study period, from 21% (95% CI 16%–25%) in 1996–2002 to 33% (29%–38%) in 2010–2016. The largest survival increases were seen for cancers of the oral cavity (reaching 44% in 2010–2016), tongue (41%), and larynx (63%), while modest changes were seen for the oropharynx (24%) and hypopharynx (17%). The latest 5-year RSR was 90% for thyroid cancers (99% for papillary carcinoma). Large female survival advantage was seen for most sites. Conclusion The observed trends suggest an emerging role of HPV infection in combination with traditional risk factors in the development of head and neck cancers in Estonia. Efforts targeting health behavior, HPV vaccination, and earlier diagnosis are crucial for reducing mortality from these cancers.

show abstract

Prostate cancer incidence, mortality and survival trends in Estonia 1995–2014

Cited by 3 publications

References 0 publications

Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine

Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine

Evaluation of long‐term living conditions in patients treated for localised prostate cancer

Incidence and Survival for Head and Neck Cancers in Estonia, 1996–2016: A Population-Based Study

Contact Info

Product

Resources

About